{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T05:49:26Z","timestamp":1677131366716},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s12020-021-02908-6","type":"journal-article","created":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T11:02:22Z","timestamp":1636196542000},"page":"537-548","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combination of pasireotide and octreotide: effects on GH and IGF-I secretion and glucose metabolism in healthy volunteers"],"prefix":"10.1007","volume":"75","author":[{"given":"Libuse","family":"Tauchmanova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Breitschaft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey","family":"Holder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin Tianxiang","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somesh","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Darstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Drutinus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Germo","family":"Gericke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert A.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto M.","family":"Pedroncelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,6]]},"reference":[{"issue":"7","key":"2908_CR1","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1210\/jcem.87.7.8665","volume":"87","author":"PU Freda","year":"2002","unstructured":"P.U. Freda, Somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab. 87(7), 3013\u20133018 (2002). https:\/\/doi.org\/10.1210\/jcem.87.7.8665","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"2908_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1006\/frne.1999.0183","volume":"20","author":"YC Patel","year":"1999","unstructured":"Y.C. Patel, Somatostatin and its receptor family. Front. Neuroendocrinol. 20(3), 157\u2013198 (1999). https:\/\/doi.org\/10.1006\/frne.1999.0183","journal-title":"Front. Neuroendocrinol."},{"issue":"1","key":"2908_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1530\/JOE-11-0224","volume":"212","author":"HA Schmid","year":"2012","unstructured":"H.A. Schmid, J. Brueggen, Effects of somatostatin analogs on glucose homeostasis in rats. J. Endocrinol. 212(1), 49\u201360 (2012). https:\/\/doi.org\/10.1530\/JOE-11-0224","journal-title":"J. Endocrinol."},{"issue":"2","key":"2908_CR4","doi-asserted-by":"publisher","first-page":"E278","DOI":"10.1152\/ajpendo.00004.2005","volume":"289","author":"J van der Hoek","year":"2005","unstructured":"J. van der Hoek, M. Waaijers, P.M. van Koetsveld, D. Sprij-Mooij, R.A. Feelders, H.A. Schmid, P. Schoeffter, D. Hoyer, D. Cervia, J.E. Taylor, M.D. Culler, S.W. Lamberts, L.J. Hofland, Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am. J. Physiol. Endocrinol. Metab. 289(2), E278\u2013E287 (2005). https:\/\/doi.org\/10.1152\/ajpendo.00004.2005","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"Suppl 4","key":"2908_CR5","doi-asserted-by":"publisher","first-page":"iv293","DOI":"10.1093\/annonc\/mdh942","volume":"15","author":"K Oberg","year":"2004","unstructured":"K. Oberg, Management of neuroendocrine tumours. Ann. Oncol. 15(Suppl 4), iv293\u2013iv298 (2004). https:\/\/doi.org\/10.1093\/annonc\/mdh942","journal-title":"Ann. Oncol."},{"issue":"11","key":"2908_CR6","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"L. Katznelson, E.R. Laws Jr, S. Melmed, M.E. Molitch, M.H. Murad, A. Utz, J.A.H. Wass, Acromegaly: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933\u20133951 (2014). https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"2908_CR7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"S. Melmed, M.D. Bronstein, P. Chanson, A. Klibanski, F.F. Casanueva, J.A.H. Wass, C.J. Strasburger, A. Luger, D.R. Clemmons, A. Giustina, A consensus statement on acromegaly therapeutic outcomes. Nat. Rev. Endocrinol. 14(9), 552\u2013561 (2018). https:\/\/doi.org\/10.1038\/s41574-018-0058-5","journal-title":"Nat. Rev. Endocrinol."},{"issue":"5","key":"2908_CR8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"C. Bruns, I. Lewis, U. Briner, G. Meno-Tetang, G. Weckbecker, SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 146(5), 707\u2013716 (2002). https:\/\/doi.org\/10.1530\/eje.0.1460707","journal-title":"Eur. J. Endocrinol."},{"issue":"11","key":"2908_CR9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/s2213-8587(14)70169-x","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"M.R. Gadelha, M.D. Bronstein, T. Brue, M. Coculescu, M. Fleseriu, M. Guitelman, V. Pronin, G. Raverot, I. Shimon, K.K. Lievre, J. Fleck, M. Aout, A.M. Pedroncelli, A. Colao, Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2(11), 875\u2013884 (2014). https:\/\/doi.org\/10.1016\/s2213-8587(14)70169-x","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"2908_CR10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"A. Colao, M.D. Bronstein, P. Freda, F. Gu, C.C. Shen, M. Gadelha, M. Fleseriu, A.J. van der Lely, A.J. Farrall, K. Hermosillo Resendiz, M. Ruffin, Y. Chen, M. Sheppard, C.S.G. Pasireotide, Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J. Clin. Endocrinol. Metab. 99(3), 791\u2013799 (2014). https:\/\/doi.org\/10.1210\/jc.2013-2480","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"2908_CR11","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"A. Colao, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, U. Schoenherr, Dipl.-Biol., D. Mills, L.R. Salgado, B.M.K. Biller, A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N. Engl J. Med. 366(10), 914\u2013924 (2012). https:\/\/doi.org\/10.1056\/NEJMoa1105743","journal-title":"N. Engl J. Med."},{"issue":"1","key":"2908_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s2213-8587(17)30326-1","volume":"6","author":"A Lacroix","year":"2018","unstructured":"A. Lacroix, F. Gu, W. Gallardo, R. Pivonello, Y. Yu, P. Witek, M. Boscaro, R. Salvatori, M. Yamada, L. Tauchmanova, M. Roughton, S. Ravichandran, S. Petersenn, B.M.K. Biller, J. Newell-Price, G. Arnaldi, H.S. Asha, T. Bandgar, A. Barkan, H. Biering, M. Bex, M. Bolanowski, M.D. Bronstein, T. Brue, D. Bruera, F. Cavagnini, A. Comlekci, C. De Block, T. Delibasi, C. Fajardo-Monta\u00f1ana, R.A. Feelders, M. Fleseriu, M.R. Gadelha, E.B. Geer, A. Heaney, G. Houde, A. Ichihara, S.A. Imran, A. Ioachimescu, P. Kadioglu, Y. Li, P. Loli, M. Nishiyama, L. Rozhinskaya, M. Ruchala, Y. Saitoh, C. Sch\u00f6fl, J. Schopohl, A. Shimatsu, C. Shimizu, T. Snabboon, P. Snyder, N. Suzaki, A. Tabarin, Y. Takahashi, S.T. Britto, G. T\u2019Sjoen, M.-C. Vantyghem, B. Velkeniers, S. Webb, S. Yamada, Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol. 6(1), 17\u201326 (2018). https:\/\/doi.org\/10.1016\/s2213-8587(17)30326-1","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"2908_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2337\/diabetes.48.1.77","volume":"48","author":"U Kumar","year":"1999","unstructured":"U. Kumar, R. Sasi, S. Suresh, A. Patel, M. Thangaraju, P. Metrakos, S.C. Patel, Y.C. Patel, Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 48(1), 77\u201385 (1999). https:\/\/doi.org\/10.2337\/diabetes.48.1.77","journal-title":"Diabetes"},{"issue":"8","key":"2908_CR14","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"R.R. Henry, T.P. Ciaraldi, D. Armstrong, P. Burke, M. Ligueros-Saylan, S. Mudaliar, Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J. Clin. Endocrinol. Metab. 98(8), 3446\u20133453 (2013). https:\/\/doi.org\/10.1210\/jc.2013-1771","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"2908_CR15","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s12020-021-02711-3","volume":"73","author":"S Chiloiro","year":"2021","unstructured":"S. Chiloiro, A. Giampietro, F. Visconti, L. Rossi, F. Donfrancesco, C.M. Fleseriu, F. Mirra, A. Pontecorvi, A. Giustina, M. Fleseriu, L. De Marinis, A. Bianchi, Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus pegvisomant. Endocrine 73(3), 658\u2013666 (2021). https:\/\/doi.org\/10.1007\/s12020-021-02711-3","journal-title":"Endocrine"},{"issue":"12","key":"2908_CR16","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1530\/EC-20-0361","volume":"9","author":"MR Gadelha","year":"2020","unstructured":"M.R. Gadelha, F. Gu, M.D. Bronstein, T.C. Brue, M. Fleseriu, I. Shimon, A.J. van der Lely, S. Ravichandran, A. Kandra, A.M. Pedroncelli, A.A.L. Colao, Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocr. Connect. 9(12), 1178\u20131190 (2020). https:\/\/doi.org\/10.1530\/EC-20-0361","journal-title":"Endocr. Connect."},{"issue":"3","key":"2908_CR17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11102-015-0684-z","volume":"19","author":"A Colao","year":"2016","unstructured":"A. Colao, R.S. Auriemma, R. Pivonello, L. Kasuki, M.R. Gadelha, Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary 19(3), 235\u2013247 (2016). https:\/\/doi.org\/10.1007\/s11102-015-0684-z","journal-title":"Pituitary"},{"issue":"5","key":"2908_CR18","doi-asserted-by":"publisher","first-page":"e0177934","DOI":"10.1371\/journal.pone.0177934","volume":"12","author":"M Kugita","year":"2017","unstructured":"M. Kugita, K. Nishii, T. Yamaguchi, A. Suzuki, Y. Yuzawa, S. Horie, E. Higashihara, S. Nagao, Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease. PLoS ONE 12(5), e0177934 (2017). https:\/\/doi.org\/10.1371\/journal.pone.0177934","journal-title":"PLoS ONE"},{"issue":"3","key":"2908_CR19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","volume":"122","author":"DS Wald","year":"2009","unstructured":"D.S. Wald, M. Law, J.K. Morris, J.P. Bestwick, N.J. Wald, Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 122(3), 290\u2013300 (2009). https:\/\/doi.org\/10.1016\/j.amjmed.2008.09.038","journal-title":"Am. J. Med."},{"issue":"3","key":"2908_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s13300-011-0006-z","volume":"2","author":"L Kuritzky","year":"2011","unstructured":"L. Kuritzky, G.P. Samraj, Enhanced glycemic control with combination therapy for type 2 diabetes in primary care. Diabetes Ther. 2(3), 162\u2013177 (2011). https:\/\/doi.org\/10.1007\/s13300-011-0006-z","journal-title":"Diabetes Ther."},{"issue":"3","key":"2908_CR21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/bcp.12698","volume":"80","author":"F Tiberg","year":"2015","unstructured":"F. Tiberg, J. Roberts, C. Cervin, M. Johnsson, S. Sarp, A.P. Tripathi, M. Linden, Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers. Br. J. Clin. Pharmacol. 80(3), 460\u2013472 (2015). https:\/\/doi.org\/10.1111\/bcp.12698","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2908_CR22","first-page":"P856","volume":"56","author":"F Tiberg","year":"2018","unstructured":"F. Tiberg, S. Glantz, K. Strangarden, C. Darstein, J. Eisinger, L. Tauchmanova, A. Breitschaft, A first-in-human pharmacokinetic, safety, and tolerability study of pasireotide subcutaneous depot. Endocrine Abstracts 56, P856 (2018)","journal-title":"Endocrine Abstracts"},{"key":"2908_CR23","doi-asserted-by":"publisher","unstructured":"J. Amaru, F. Barbieri, M. Arvigo, A. Solari, A. Bajetto, F. Nista, C. Campana, G. Gaggero, A. Prior, D. Criminelli Rossi, G. Zona, D. Ferone, T. Florio, F. Gatto, Octreotide and pasireotide combination treatment in somatotroph tumor cells: predominant role of SST2 in mediating ligand effects. Cancers 13(8) (2021). https:\/\/doi.org\/10.3390\/cancers13081816","DOI":"10.3390\/cancers13081816"},{"issue":"8","key":"2908_CR24","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/BF03346419","volume":"31","author":"R Attanasio","year":"2008","unstructured":"R. Attanasio, A. Mainolfi, F. Grimaldi, R. Cozzi, M. Montini, C. Carzaniga, S. Grottoli, L. Cortesi, M. Albizzi, R.M. Testa, L. Fatti, D. De Giorgio, C. Scaroni, F. Cavagnini, P. Loli, G. Pagani, E. Ghigo, Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients. J. Endocrinol. Investig. 31(8), 704\u2013710 (2008). https:\/\/doi.org\/10.1007\/BF03346419","journal-title":"J. Endocrinol. Investig."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02908-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-021-02908-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02908-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T13:46:45Z","timestamp":1643982405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-021-02908-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,6]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["2908"],"URL":"https:\/\/doi.org\/10.1007\/s12020-021-02908-6","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,6]]},"assertion":[{"value":"12 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"L.T. is a former employee of Novartis. A.B. is an employee of Parexel International GmbH; Parexel International GmbH was paid by Novartis Pharma AG for assistance in conducting the study. G.H., K.T.H., S.C., C.D., M.P., E.D., G.G. and H.A.S. are employees of Novartis. A.M.P. is a former employee of Novartis and a current employee of Recordati.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol and all amendments were reviewed and approved by the Berlin State Ethics Committee (Turmstra\u00dfe 21, Haus A, Berlin 10559, Germany). The study was conducted according to the ICH E6 Guideline for Good Clinical Practice and the ethical principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All subjects provided written consent to participate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}